Aptevo Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
APVO$1.13-8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $21,619 | $8,714 |
| Prepaid expenses and other current assets | 1,462 | 1,945 |
| Total current assets | 23,081 | 10,659 |
| Property and equipment, net | 303 | 543 |
| Operating lease right-of-use asset | 3,810 | 4,389 |
| Total assets | $27,194 | $15,591 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $877 | $1,242 |
| Accrued expenses and other current liabilities | 4,307 | 4,197 |
| Operating lease liability, current portion | 866 | 768 |
| Total current liabilities | 6,050 | 6,207 |
| Operating lease liability, net of current portion | 3,763 | 4,629 |
| Total liabilities | 9,813 | 10,836 |
| Stockholders' equity: | ||
| Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding | — | — |
| Common stock: $0.001 par value; 500,000,000 shares authorized; 997,830 and 4,051 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 114 | 84 |
| Additional paid-in capital | 292,382 | 252,248 |
| Accumulated deficit | (275,115) | (247,577) |
| Total stockholders' equity | 17,381 | 4,755 |
| Total liabilities and stockholders' equity | $27,194 | $15,591 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.